YKL-40 levels were higher in patients with poor outcome (237.0 [139.5, 284.1] versus 119.6 [63.5, 193.0] ng/mL, P < 0.001), all-cause mortality (244.9 [159.1, 279.5] versus 126.7 [73.9, 230.8] ng/mL, P < 0.001), and recurrent stroke (176.2 [105.8, 258.1] versus 135.8 [81.3, 242.1] ng/mL, P = 0.013). Here, CHI3L1 is linked to stroke disorder.